Our review of biopharma dealmaking – for the third quarter of 2013. Our data come from Elsevier’s Strategic Transactions.
Biopharma companies closed the third quarter of 2013 with an aggregate $4.6 billion in financing, a 58% drop from the...
Biopharma Dealmaking Quarterly Statistics, Q3 2013
A look at the financing, M&A, and alliance activity July-September 2013
Biopharma financing in Q3 2013 totaled $4.6 billion, a 58% drop from the second quarter; Perrigo’s $8.3 billion acquisition of Elan made up more than half of the M&A dollar value; and marketed products made up the majority of licensed products.